undamentalytics Newsletter
Sign in

Cardiff Oncology, Inc. balance sheet

At the end of fiscal 2025, Cardiff Oncology, Inc. had total assets of $61.9m, total liabilities of $16.5m and shareholders' equity of $45.4m. It held $17.5m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents111266767148111013112162251179
Receivables0000000000110100
Total current assets111262868399131113314611177956036
Total assets1122729714412141313515011682976237
Accounts payable1001111111122584
Total current liabilities11248843567810131611
Long-term debt——01311140—0———————
Total debt0011517173—00000000
Total liabilities597212324646791012141611
Shareholders' equity−422084920710712814010670834527
Shares outstanding54m62m—95m—153m2m———42m45m45m—68m69m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CRDF vs CRVOCRDF vs MNOVCRDF vs STTK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cardiff Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cardiff Oncology, Inc.